EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, ...
Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...
Though he doesn't remember it, Branden Baptiste had his first sickle cell crisis at age 2. Through elementary school, he was ...
Everyday Health on MSN4 天
Sickle Cell Anemia Symptoms
The hallmark symptom of sickle cell anemia is pain, particularly episodes of sudden pain, sometimes called sickle cell crises ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
A drug developed by Sanofi raised platelet counts and reduced bleeding episodes in patients with a rare autoimmune disorder ...
Beam Therapeutics (BEAM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...
When you give to Light Up A Lawn, Light Up A Life, you are supporting programs like Nationwide Children's cutting-edge gene ...
Though he doesn't remember it, Branden Baptiste had his first sickle cell crisis at age 2. Through elementary school, he was ...
The latest announcement is out from Beam Therapeutics ( (BEAM) ).
Beam Therapeutics (BEAM) announced new data for its Engineered Stem Cell Antibody Evasion, or ESCAPE, conditioning platform.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...